EXHIBIT B CLEAN VERSION OF PENDING CLAIMS U.S. PATENT APPLICATION NO. 09/657,722

- 19. A composition comprising a recovered population of peptides in admixture with a pharmaceutically acceptable non toxic carrier, wherein said recovered population of peptides is produced by a method comprising the steps of:
 - purifying a population of stress protein-peptide complexes from mammalian tumor cells, wherein the stress protein is non covalently associated with the peptide in said complexes;
 - (b) releasing the peptides from said population of complexes to produce a released population of peptides; and
 - (c) recovering the released population of peptides.
 - 22. The composition of claim 19 further comprising a cytokine.
- 23. The composition of claim 22 wherein said cytokine is selected from the group consisting of IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IFN α , IFN β , IFN γ , TNF α , TNF β , G-CSF, GM-CSF, and TGF- β .
- 24. The composition of claim 19 wherein the peptides are released from said population of complexes by a method comprising placing said population of complexes in the presence of adenosine triphosphate, low pH, or both.
- 25. The composition of claim 19, wherein said mammalian tumor cells are human cells.
- 26. The composition of claim 19 wherein said mammalian tumor cells are from a tumor selected from the group consisting of melanocarcinoma, hepatocarcinoma, and renal cell carcinoma.
- 27. The composition of claim 19 wherein said tumor cells are from a metastasis.

- 28. The composition of claim 19, wherein said tumor cells have been proliferated in vivo.
- 29. The composition of claim 19, wherein said tumor cells have been proliferated in vitro.
- 30. The composition of claim 19, wherein the stress protein is a member of a stress protein family selected from the group consisting of hsp60, hsp70, and hsp90.
 - 31. The composition of claim 19, wherein the stress protein is gp96.